BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28196759)

  • 1. Follow-up MR imaging of PI-RADS 3 and PI-RADS 4 prostate lesions.
    Hauth E; Jaeger H; Hohmuth H; Beer M
    Clin Imaging; 2017; 43():64-68. PubMed ID: 28196759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
    Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
    World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
    Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
    World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?
    Drobish JN; Bevill MD; Tracy CR; Sexton SM; Rajput M; Metz CM; Gellhaus PT
    Urol Oncol; 2021 Apr; 39(4):235.e1-235.e4. PubMed ID: 33451935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
    Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
    Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-bore MR prostate biopsy - initial experience.
    Rembak-Szynkiewicz J; Wojcieszek P; Hebda A; Mazgaj P; Badziński A; Stasik-Pres G; Chmielik E; Bobek-Billewicz B
    Endokrynol Pol; 2022; 73(4):712-724. PubMed ID: 35971938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Biopsy Does Not Contribute to Disease Upgrading in Patients Undergoing Targeted Biopsy for PI-RADS 5 Lesions Identified on Magnetic Resonance Imaging in the Course of Active Surveillance for Prostate Cancer.
    Arabi A; Deebajah M; Yaguchi G; Pantelic M; Williamson S; Gupta N; Park H; Peabody J; Menon M; Dabaja A; Alanee S
    Urology; 2019 Dec; 134():168-172. PubMed ID: 31479660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
    Chen F; Cen S; Palmer S
    Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.
    Borofsky S; George AK; Gaur S; Bernardo M; Greer MD; Mertan FV; Taffel M; Moreno V; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    Radiology; 2018 Jan; 286(1):186-195. PubMed ID: 29053402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the «cognitive» biopsy in the diagnosis of prostate cancer in patients with a previous negative biopsy.
    Barbas Bernardos G; Herranz Amo F; de Miguel Campos E; Luis Cardo A; Herranz Arriero A; Caño Velasco J; Cancho Gil MJ; Jara Rascón J; Mayor de Castro J; Hernández Fernández C
    Actas Urol Esp (Engl Ed); 2019; 43(1):12-17. PubMed ID: 30131167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer.
    Tan N; Lin WC; Khoshnoodi P; Asvadi NH; Yoshida J; Margolis DJ; Lu DS; Wu H; Sung KH; Lu DY; Huang J; Raman SS
    Radiology; 2017 Apr; 283(1):130-139. PubMed ID: 27861110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.
    Renard-Penna R; Mozer P; Cornud F; Barry-Delongchamps N; Bruguière E; Portalez D; Malavaud B
    Radiology; 2015 May; 275(2):458-68. PubMed ID: 25599415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
    Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
    Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.
    Osses DF; van Asten JJ; Kieft GJ; Tijsterman JD
    World J Urol; 2017 Feb; 35(2):207-212. PubMed ID: 27287889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.